Introduction
Chronic liver disease has become an increasing health burden worldwide. In 2015, cirrhosis and chronic liver diseases accounted for 2% of worldwide deaths, with a relative increase of 10.3% from 2005 (1) . There are significant variations in mortality among different regions of the world with Mokdad et al (2) reporting liver cirrhosis as a health priority in Central Asia, Central Europe, Eastern Europe and Central Latin America. Increasing mortality rates are attributable to viral hepatitis but also driven by the increasing prevalence of alcoholic liver disease (ALD) and non-alcoholic fatty liver disease (NAFLD) which are now the most common causes of chronic liver disease in the Western world (3) (4) (5) .
Due to the increasing morbidity and mortality of chronic liver disease there is a necessity for urgent action to be taken to prioritise the earlier identification and treatment of patients, particularly within the community (6) . Commonly used diagnostic tests have poor sensitivity and specificity, are completed opportunistically or are not appropriate to be used within a community setting therefore limiting the opportunities for intervening at an earlier stage in the disease. This results in nearly 50% of patients only receiving their diagnosis of cirrhosis following an emergency admission to hospital with a decompensating event (7) . A liver biochemistry panel often referred to as Liver function tests (LFTs) are inappropriately relied upon in the community setting to identify patients with asymptomatic chronic liver disease (8) (9) (10) . Fracanzani et al(11) demonstrated that 59% of patients with a histological diagnosis of NASH had a normal serum alanine aminotransferase (ALT) level and would not have been identified by current diagnostic algorithms.
At present, an evidenced based risk stratification pathway does not exist within a community setting to screen the general or a targeted population who are at risk of chronic liver disease. Until recently a barrier has been the absence of a robust and reproducible screening tool. Non-invasive tests of liver fibrosis represent such a tool and their utility in hospital practice has been supported by a number of international organisations including recent guidelines by EASL (12) . However, the majority of evidence has been derived and validated from populations based within secondary care (13) (14) (15) and thus extrapolation of these tests to a cohort in the community may not be valid due to a reliance upon abnormal LFTs instigating referral for specialist advice, a different prevalence of disease and spectrum bias.
To facilitate the emergence of strategies which aim to risk stratify patients in a general population/community setting we have systematically reviewed the available evidence. From this, the scale of undiagnosed chronic liver disease can be estimated, the inadequacy of current referral pathways can be highlighted and an optimal risk stratification strategy potentially proposed. As the commonest causes of chronic liver disease are ALD and NAFLD we have focussed on the non-invasive tests which have been used to stratify patients at risk of these aetiologies.
Aims
The primary aim of this systematic review was to determine the proportion of the studied populations found to have clinically significant liver disease as defined by the non-invasive tests used in the individual studies.
The secondary aims of this systematic review were i) to identify the proportion of patients with liver fibrosis or cirrhosis as defined by the non-invasive test who had normal ALT results, ii) to evaluate the difference in the proportion of patients identified as having liver disease using non-invasive tests between unselected or targeted populations within a community setting and iii) to determine the patient variables which are significant in identifying patients with liver fibrosis.
Methods
This review was conducted in accordance with the Cochrane Handbook for Systematic Reviews of interventions (16) and the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRIMSA) guidelines (17) .
Search strategy
Two reviewers (RH and DH) defined key MeSH headings and free text search terms relevant to the participants involved in the studies, the two aetiologies of chronic liver disease, the community setting and the non-invasive tests used to stratify for liver fibrosis. Subsequently, a search algorithm was derived in collaboration with a local librarian (Alison Ashmore; University of Nottingham); the final search algorithms including the MeSH terms used within the specific electronic databases are listed within the appendix. Two independent searches of EMBASE (January 1980 to January 2015), MEDLINE (January 1946 to January 2015) and Web of Science were completed. Additionally a hand search was completed of all major UK and worldwide conference proceedings dating back to 2010 including the British Society of Gastroenterology, the British Association for the study of liver disease, the European Association for the study of liver disease and the American Association for the study of liver disease. A targeted search was also completed of reference lists from the original studies and abstracts including any review articles or citations that were identified.
Identification of studies was commenced in November 2014 and completed in January 2015. The titles and abstracts of all studies identified within the literature search were screened to determine their suitability for inclusion within the review. The full texts of all studies considered to be suitable were assessed for eligibility. Any disagreements were discussed but if these could not be resolved the advice from a third reviewer (ING) was sought.
Selection criteria
Listed below are the eligibility criteria used to screen the individual studies for inclusion within the review.
Studies were included if: i) the study was performed in adults defined as 18 years or older, ii) the study population was from a non-hospital setting e.g. community, primary care or outreach unit, iii) study participants underwent a validated non-invasive test which would stratify for liver fibrosis, iv) the prevalence of clinically significant liver disease, either liver fibrosis or cirrhosis was reported as an outcome measure by the study (validation of the result by histopathology was not an absolute requirement) and v) participants were recruited from an unselected population or based upon the participants age or a defined risk factor for ALD or NAFLD. Studies were excluded if: i) data regarding the study population, the setting in which the non-invasive test was completed or the threshold for the non-invasive test was not adequately reported, ii) the participants were solely investigated for liver disease aetiologies other than ALD or NAFLD (e.g. viral hepatitis) or iii) they were not published in the English language
Data collection and analysis
Data extraction was completed and reviewed by the two researchers independently. This included data on study characteristics, demographics of the patient population and details of the non-invasive test which was used. The outcome measure was the reported prevalence of liver fibrosis and/or cirrhosis within the population studied as defined by the non-invasive test which was used. Due to the lack of comparable studies and substantial heterogeneity a meta-analysis could not be performed. 
Results
Our systematic search of bibliographic databases identified a total of 813 citations. An additional 7 studies were identified from the grey literature. Following screening of the titles and abstracts, a total of 779 studies were excluded. The full text of 41 studies was assessed against the inclusion and exclusion criteria resulting in a further 22 studies being excluded from the final analysis. Finally, 19 studies including 17 full journal articles and 2 abstracts were included within the systematic review.
The overall results of the search strategy are presented in figure 1.
Non-invasive tests used:
Eleven different non-invasive tests were utilised to stratify patients for liver fibrosis. Transient elastography (TE) was the only imaging based modality and was the most frequently used test body mass index≥28 kg/m 2 (1 point)) , Hyaluronic acid, the ELF score (enhanced liver fibrosis) and the Southampton traffic light test which were all used once within separate studies. The baseline characteristics of individual studies including patient demographics are reported within Table 1 .
Target population:
There was significant heterogeneity in the community studies included for analysis ( Table 1) . The initial target population tested by the non-invasive tests varied. Five studies stratified members of the general population according to an age cut off whilst a further 5 studies stratified an unselected group of adults. The prevalence of risk factors reported within these studies would be as expected for the general population apart from the study by You et al (18) in which the prevalence of type 2 diabetes was raised at 11.9%. Ten studies stratified patients with risk factors for NAFLD including 3 studies(19-21) which completed subgroup analysis on patients initially identified from the general population.
Four studies stratified patients known to be at risk of ALD including 1 study(19) which had completed further subgroup analysis. Heterogeneity also existed in the choice of non-invasive test and outcome measure, including the severity of liver fibrosis.
Screening uptake
The proportion of patients that participated in screening from the invited study population was reported in eight studies. This ranged from 20%-89% for the first study visit. In studies which had multiple steps within the algorithm(22,23) a decline in uptake was observed. In the study by Sheron et al(22) a positive AUDIT questionnaire was recorded in 24.3%, however only 34.8% of this group subsequently attended clinic for the non-invasive test to be completed.
Prevalence of fibrosis
All 19 studies reported the prevalence of liver fibrosis according to a specified threshold for the noninvasive test which was utilised.
Unselected population
In those studies reporting unselected patients from the general population the prevalence of liver fibrosis ranged from 2%-19% (Table 2 ). All 5 studies utilised TE but the results varied due to the different liver stiffness thresholds that were chosen and the degree of liver fibrosis that was estimated. The lowest estimate obtained in the study by Wong et al (20) used the highest threshold of 9.6kPa and estimated the prevalence of advanced liver fibrosis only. The highest estimate in the study by Malik et al (24), used a lower threshold of 7.0kPa and estimated the prevalence for any liver fibrosis.
In the 5 studies which stratified members of the general population according to an age cut off, the prevalence ranged from 0.7%-25.7%. The lowest estimate obtained in the study by Poynard et al (23) used a two-step approach with only half of the patients re-attending for the second test. Overall only two studies stratified members of the general population for advanced liver fibrosis. The reported prevalence was 0.9% (25) and 2%(20) using Fibrotest ≥0.59 and TE ≥ 9.6kPa respectively.
NAFLD
In the ten studies which stratified patients identified to be at risk of NAFLD the reported prevalence of liver fibrosis ranged from 0% -92.6% (see appendix p3). Again, the prevalence varied dependent on the non-invasive test which was used and the degree of liver fibrosis that was being estimated. In the 5 studies which estimated any liver fibrosis the prevalence ranged between 0.4%-92.6%. The studies which reported the highest estimates of prevalence were Williamson et al (26) and Morling et al (27) in which 100% of the study populations were reported to have type 2 diabetes. Four studies estimated the prevalence of advanced liver fibrosis which ranged from 0%-27.9%. The highest estimate was obtained from Vesey et al (21) who only recruited patients aged over 65 years, therefore increasing the probability of disease being identified. The lowest estimate was obtained in the study by Wong et al (20) who utilised several non-invasive tests to demonstrate the prevalence of advanced liver fibrosis.
In this cohort, use of the NAFLD fibrosis score≥0.676 and APRI≥1.5 estimated a 0% prevalence for advanced fibrosis, while using TE≥9.6kPa and AST:ALT ratio≥1.0 the prevalence increased to 3.7% and 12.1% respectively.
ALD
In the four studies which stratified patients identified to be at risk of ALD the reported prevalence ranged between 11%-20.5% (see appendix p3). In the three studies (19, 28, 29) which utilised TE the reported disease prevalence was similar despite two different thresholds being chosen and the reported outcome measures being different.
Prevalence of cirrhosis
Only seven studies reported the prevalence of cirrhosis which varied depending on the study population being stratified (Table 3 ). In the four studies which used subjects from the general population the reported prevalence varied between 0.1%-1.7%. The highest estimate was obtained by
Malik et al(24) but they did not report the risk factor prevalence in the study population. It cannot therefore be determined why this self-selected group were at increased risk of having clinically significant liver disease. The other three studies which stratified patients due to an underlying risk factor reported a prevalence of 2.4%-4.0%; a much higher estimate of liver cirrhosis prevalence compared to studies of the general population. Interestingly, in the study by Das et al (30) which reported a cirrhosis prevalence of 2.4% in patients with NAFLD, the prevalence of cirrhosis in their unselected cohort was calculated to be 0.2%; equivalent to the estimates reported in the other studies of the general population.
Liver biopsy results
Only six studies utilised histology on liver biopsy to confirm the diagnosis of liver fibrosis/cirrhosis as indicated by the non-invasive test (Table 4 ). This includes 5 studies which used TE, all of which used different thresholds of liver stiffness, and 1 study which used Fibrotest. Within no study were liver biopsies completed in all of the patients undergoing the non-invasive test.
Across the 6 studies, the acceptance rate of liver biopsies varied between 22.5%-87.5%. In the study 
ALT levels and predictors of significant liver disease
Nine studies have reported the percentage of patients with an abnormal test result who had normal ALT levels. This indicates the percentage of patients who would traditionally not have been identified though current referral algorithms which are based upon abnormal LFTs. Two studies by Wong et al (20) and Grattagliano et al (34) used conservative ALT levels of >19IU/L for women and >30IU/L for men as suggested by Prati et al (35) whilst the remaining studies used the more traditional cut offs.
The percentage of patients with liver fibrosis who had a normal ALT level in the studies of the general population ranged from 40%-74.6% and in those which identified patients with an underlying risk factor ranged from 26.5%-87.5% respectively. The lowest estimates reported within both ranges were seen within the two studies which utilised the more conservative cut offs. Of the three studies which used traditional cut offs in the patient populations with an underlying risk factor, 72.4%-87.5% of patients had a normal ALT level and would not have been routinely identified.
Harman et al (29) was the only study which reported the percentage of patients with a normal ALT level who were diagnosed with cirrhosis. In this study 90.9% of patients with asymptomatic compensated cirrhosis would not have been identified via traditional community based algorithms.
Predictors of clinically significant liver disease
Five studies completed a multivariate analysis to identify the variables which independently predict an outcome of elevated liver stiffness using TE or significant/confirmed fibrosis from a non-invasive test result (see appendix p4). The key variables identified include a raised BMI, an elevated waist circumference), an abnormal ALT, the age of the patient and being male.
Discussion
This review has demonstrated that a number of non-invasive tests have the ability to stratify for the severity of liver disease within a community setting. Moreover, when compared to the uptake of other screening programs, the participation of those invited suggests that as screening tests for use in the community they are acceptable to patients. The estimates of cirrhosis prevalence (0.1%-1.7%) are greater than previously reported (0.07-0.13%) (36, 37) highlighting the burden of undiagnosed chronic liver disease in the general population and that the true population prevalence is still yet to be established. The presence of normal liver function tests in both significant liver disease (ranging from 41% to 75 %) and cirrhosis (90 % in one study) is a stark reminder of the limitations of these tests to detect chronic liver injury.
In this review eleven different non-invasive tests were used within heterogeneous population groups.
The variation in reported disease prevalence highlights the uncertainty as to which test is most appropriate as demonstrated specifically in the studies by Morling et al (27) and Wong et al (20) who applied several non-invasive tests to the same cohort of patients resulting in widely differing estimates of prevalence for any liver fibrosis (0.4%-63.8%) and advanced liver fibrosis (0%-12.1%) respectively.
Moreover, comparing studies which used the same non-invasive test provided no further clarity as different thresholds were used for the stratification of liver fibrosis. However, as demonstrated by
Roulot et al (31) and Moessner et al (28) , even when similar liver stiffness thresholds for transient elastography were used a wide variation in the histological diagnoses can be observed. The variation in thresholds may be a result of using normal populations to determine thresholds. Roulot et al (38) defined a threshold of 8kPa, based upon the 95 th centile, in a healthy population, in contrast to the study by Conti et al which reported the 95 th centile at 6.8kPa (39). The differences observed may be due to the younger age of participants in the study by Conti (patients in the cohort were between 30 and 60 years of age), or the separate analysis of patients with ultrasound evidence of NAFLD and hence a lower prevalence of metabolic syndrome risk factors. The normal thresholds of Fibrotest have been defined in healthy blood donors(40) and are consistent with the index validation study using the biopsy as a reference standard(41). This demonstrates that the optimal threshold for defining a specific degree of liver fibrosis is yet to be agreed. There also appears to be no concordance over which stage of liver fibrosis is clinically important with studies reporting the prevalence of any, significant or advanced liver fibrosis as their outcome measure. In NAFLD, it has been shown that patients with ≥F3 fibrosis have an increased risk of mortality predominantly from cardiovascular and liver related disease(42, 43).
It is obvious that use of a liver biopsy as a screening tool is not feasible due to the practicalities of performing an invasive procedure in a community setting, the expense and the low prevalence of disease; in combination this results in an unfavourable risk/benefit ratio. Currently all non-invasive tests continue to be validated against histological findings which have their own well documented limitations(44). From the studies within this review the true diagnostic performance could not be established as a liver biopsy was not completed on all of the patients with an abnormal test result or any patient with a negative test result. Although formal analysis of the quality of included studies was not performed as they were in essence diagnostic prevalence studies for which a relevant validated quality assessment tool was not found, one must consider all included studies to be at high risk of methodological bias due to the inherent selection bias for liver biopsy (where performed). Completion of longitudinal cohort studies would enable the true diagnostic performance of a non-invasive test to be assessed along with identifying and validating the optimum threshold that should be applied. These studies are also imperative given the emerging evidence of the additional prognostic information that these non-invasive markers could provide (14, 42) . Boursier et al (45) 
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